TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective Randomized Comparative Study of Efficacy and Safety of Combined Deferiprone (DFP) and Deferasirox Versus DFP and Desferrioxamine (DFO) Therapy in Diseases With Severe Iron Overload
Brief Summary: Interventional Allocation: Randomized Endpoint Classification: Safety/Efficacy Study of combined chelation therapy Masking: Open Label Primary Purpose: Treatment of transfusional iron overload

Primary Outcome Measures:

• The primary outcome measure is to assess efficacy in lowering serum ferritin level(the change in serum ferritin compared to baseline) with combining DFP and deferasirox compared to combined DFP and DFO in conditions with severe chronic iron overload; showing an up-trend of SF over previous 12 months on single chelator.

Secondary Outcome Measures:

• The secondary outcome measure is to determine the number of patients who will develop adverse events in order to assess safety upon administering the drugs in combination (DFP and DFX) compared to the combination of DFO and DFP.


Options:
A: Arm Label: Thalassemia cohort; Type: N/A; Interventions: N/A | Arm Label: Successful SCT cohort; Type: N/A; Interventions: N/A
B: Arm Label: arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: DFP (ferriprox) and deferasirox (ICL 670) | Arm Label: arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: DFP, DFO | Intervention Type: DRUG; Name: DFP (ferriprox) and deferasirox (ICL 670); Assigned to Arm(s): arm 1 | Intervention Type: DRUG; Name: DFP, DFO; Assigned to Arm(s): arm 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Deferiprone (DFP) and Deferoxamine (DFO) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Deferiprone (DFP) | Intervention Type: DRUG; Name: Deferiprone (DFP) and Deferoxamine (DFO); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Deferiprone (DFP); Assigned to Arm(s): 2
D: Arm Label: Deferiprone; Type: EXPERIMENTAL; Interventions: Drug: Deferiprone | Arm Label: Deferasirox; Type: ACTIVE_COMPARATOR; Interventions: Drug: Deferasirox | Intervention Type: DRUG; Name: Deferiprone; Assigned to Arm(s): Deferiprone | Intervention Type: DRUG; Name: Deferasirox; Assigned to Arm(s): Deferasirox

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective Randomized Comparative Study of Efficacy and Safety of Combined Deferiprone (DFP) and Deferasirox Versus DFP and Desferrioxamine (DFO) Therapy in Diseases With Severe Iron Overload
Brief Summary: Interventional Allocation: Randomized Endpoint Classification: Safety/Efficacy Study of combined chelation therapy Masking: Open Label Primary Purpose: Treatment of transfusional iron overload

Primary Outcome Measures:

• The primary outcome measure is to assess efficacy in lowering serum ferritin level(the change in serum ferritin compared to baseline) with combining DFP and deferasirox compared to combined DFP and DFO in conditions with severe chronic iron overload; showing an up-trend of SF over previous 12 months on single chelator.

Secondary Outcome Measures:

• The secondary outcome measure is to determine the number of patients who will develop adverse events in order to assess safety upon administering the drugs in combination (DFP and DFX) compared to the combination of DFO and DFP.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Deferiprone (DFP) and Deferoxamine (DFO) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Deferiprone (DFP) | Intervention Type: DRUG; Name: Deferiprone (DFP) and Deferoxamine (DFO); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Deferiprone (DFP); Assigned to Arm(s): 2
B: Arm Label: arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: DFP (ferriprox) and deferasirox (ICL 670) | Arm Label: arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: DFP, DFO | Intervention Type: DRUG; Name: DFP (ferriprox) and deferasirox (ICL 670); Assigned to Arm(s): arm 1 | Intervention Type: DRUG; Name: DFP, DFO; Assigned to Arm(s): arm 2
C: Arm Label: ICL670 (Deferasirox); Type: EXPERIMENTAL; Interventions: Drug: Deferasirox | Intervention Type: DRUG; Name: Deferasirox; Assigned to Arm(s): ICL670 (Deferasirox)
D: Arm Label: Thalassemia cohort; Type: N/A; Interventions: N/A | Arm Label: Successful SCT cohort; Type: N/A; Interventions: N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective Randomized Comparative Study of Efficacy and Safety of Combined Deferiprone (DFP) and Deferasirox Versus DFP and Desferrioxamine (DFO) Therapy in Diseases With Severe Iron Overload
Brief Summary: Interventional Allocation: Randomized Endpoint Classification: Safety/Efficacy Study of combined chelation therapy Masking: Open Label Primary Purpose: Treatment of transfusional iron overload

Primary Outcome Measures:

• The primary outcome measure is to assess efficacy in lowering serum ferritin level(the change in serum ferritin compared to baseline) with combining DFP and deferasirox compared to combined DFP and DFO in conditions with severe chronic iron overload; showing an up-trend of SF over previous 12 months on single chelator.

Secondary Outcome Measures:

• The secondary outcome measure is to determine the number of patients who will develop adverse events in order to assess safety upon administering the drugs in combination (DFP and DFX) compared to the combination of DFO and DFP.


Options:
A: Arm Label: arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: DFP (ferriprox) and deferasirox (ICL 670) | Arm Label: arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: DFP, DFO | Intervention Type: DRUG; Name: DFP (ferriprox) and deferasirox (ICL 670); Assigned to Arm(s): arm 1 | Intervention Type: DRUG; Name: DFP, DFO; Assigned to Arm(s): arm 2
B: Arm Label: 5 mg/kg/day deferasirox; Type: EXPERIMENTAL; Interventions: Drug: deferasirox, Drug: placebo | Arm Label: 10 mg/kg/day deferasirox; Type: EXPERIMENTAL; Interventions: Drug: deferasirox, Drug: placebo | Arm Label: 5 mg/kg/day placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: 10 mg/kg/day placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: deferasirox; Assigned to Arm(s): 10 mg/kg/day deferasirox, 5 mg/kg/day deferasirox | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 10 mg/kg/day deferasirox, 10 mg/kg/day placebo, 5 mg/kg/day deferasirox, 5 mg/kg/day placebo
C: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Deferoxamine | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Deferasirox | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: Deferoxamine, Drug: Deferasirox | Intervention Type: DRUG; Name: Deferoxamine; Assigned to Arm(s): Arm 1, Arm 3 | Intervention Type: DRUG; Name: Deferasirox; Assigned to Arm(s): Arm 2, Arm 3
D: Arm Label: ICL670 (Deferasirox); Type: EXPERIMENTAL; Interventions: Drug: Deferasirox | Intervention Type: DRUG; Name: Deferasirox; Assigned to Arm(s): ICL670 (Deferasirox)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Dialectical Behavior Therapy in Patient With Self Harming Behavior and Traits Within the Spectrum of Borderline Personality Disorder.
Brief Summary: Purpose: The purpose of this study is to investigate the efficacy of Dialectical Behavior Therapy (DBT) versus CAMS (Collaborative Assessment and Management of Suicidality) -informed supportive psychotherapy on the risk of self-harm acts and suicide attempts in patients with self behavior and personality traits within the spectrum of borderline personality disorder.

Hypothesis: The hypothesis is 16 weeks of treatment with Dialectical Behavior Therapy (DBT) after a defined manual has a higher efficacy than CAMS-informed supportive psychotherapy on self-harm acts, suicide attempts, suicidal ideation, depressive symptoms, impulsiveness and consumption of hospital services in patients with symptoms within the spectrum of borderline personality disorder (BDP).

Method: The investigators will include 160 patients in the randomized trial to investigate whether 16 weeks of DBT-treatment as a higher efficacy than CAMS-informed supportive psychotherapy on the risk of self-harm acts and suicide attempts in patients with self-harm behavior and personality traits within the spectrum of borderline personality disorder. The trial will meet strict criteria for high quality randomized trials, and will hopefully help to establish evidence for the treatment of this patient group at higher risk of later suicide. There will be performed follow up interviews after 16 weeks, 28 weeks and 52 weeks.


Options:
A: Arm Label: Dialectical Behavior Therapy DBT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DBT | Arm Label: CAMS; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: CAMS | Intervention Type: BEHAVIORAL; Name: DBT; Assigned to Arm(s): Dialectical Behavior Therapy DBT | Intervention Type: BEHAVIORAL; Name: CAMS; Assigned to Arm(s): CAMS
B: Arm Label: CAMS treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Psychotherapy | Arm Label: Treatment as usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Psychotherapy | Intervention Type: BEHAVIORAL; Name: Psychotherapy; Assigned to Arm(s): CAMS treatment, Treatment as usual
C: Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Risperidone | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Risperidone | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): 1, 2
D: Arm Label: 1; Type: OTHER; Interventions: Drug: Naltrexone | Arm Label: 2; Type: OTHER; Interventions: Drug: Naltrexone | Arm Label: 3; Type: OTHER; Interventions: Drug: Naltrexone | Arm Label: 4; Type: OTHER; Interventions: Drug: Naltrexone | Intervention Type: DRUG; Name: Naltrexone; Assigned to Arm(s): 1, 2, 3, 4

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Dialectical Behavior Therapy in Patient With Self Harming Behavior and Traits Within the Spectrum of Borderline Personality Disorder.
Brief Summary: Purpose: The purpose of this study is to investigate the efficacy of Dialectical Behavior Therapy (DBT) versus CAMS (Collaborative Assessment and Management of Suicidality) -informed supportive psychotherapy on the risk of self-harm acts and suicide attempts in patients with self behavior and personality traits within the spectrum of borderline personality disorder.

Hypothesis: The hypothesis is 16 weeks of treatment with Dialectical Behavior Therapy (DBT) after a defined manual has a higher efficacy than CAMS-informed supportive psychotherapy on self-harm acts, suicide attempts, suicidal ideation, depressive symptoms, impulsiveness and consumption of hospital services in patients with symptoms within the spectrum of borderline personality disorder (BDP).

Method: The investigators will include 160 patients in the randomized trial to investigate whether 16 weeks of DBT-treatment as a higher efficacy than CAMS-informed supportive psychotherapy on the risk of self-harm acts and suicide attempts in patients with self-harm behavior and personality traits within the spectrum of borderline personality disorder. The trial will meet strict criteria for high quality randomized trials, and will hopefully help to establish evidence for the treatment of this patient group at higher risk of later suicide. There will be performed follow up interviews after 16 weeks, 28 weeks and 52 weeks.


Options:
A: Intervention Type: BEHAVIORAL; Name: Cognitive Therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Supportive Therapy; Assigned to Arm(s): N/A
B: Arm Label: meditation; Type: EXPERIMENTAL; Interventions: Behavioral: Central Meditation and Imagery Therapy | Arm Label: wait list; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Central Meditation and Imagery Therapy; Assigned to Arm(s): meditation
C: Arm Label: Dialectical Behavior Therapy DBT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DBT | Arm Label: CAMS; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: CAMS | Intervention Type: BEHAVIORAL; Name: DBT; Assigned to Arm(s): Dialectical Behavior Therapy DBT | Intervention Type: BEHAVIORAL; Name: CAMS; Assigned to Arm(s): CAMS
D: Arm Label: MBT therapy plus treatment as usual; Type: EXPERIMENTAL; Interventions: Other: Mentalization-Based Group Therapy for Adolescents | Arm Label: Treatment as usual alone; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Mentalization-Based Group Therapy for Adolescents; Assigned to Arm(s): MBT therapy plus treatment as usual

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Dialectical Behavior Therapy in Patient With Self Harming Behavior and Traits Within the Spectrum of Borderline Personality Disorder.
Brief Summary: Purpose: The purpose of this study is to investigate the efficacy of Dialectical Behavior Therapy (DBT) versus CAMS (Collaborative Assessment and Management of Suicidality) -informed supportive psychotherapy on the risk of self-harm acts and suicide attempts in patients with self behavior and personality traits within the spectrum of borderline personality disorder.

Hypothesis: The hypothesis is 16 weeks of treatment with Dialectical Behavior Therapy (DBT) after a defined manual has a higher efficacy than CAMS-informed supportive psychotherapy on self-harm acts, suicide attempts, suicidal ideation, depressive symptoms, impulsiveness and consumption of hospital services in patients with symptoms within the spectrum of borderline personality disorder (BDP).

Method: The investigators will include 160 patients in the randomized trial to investigate whether 16 weeks of DBT-treatment as a higher efficacy than CAMS-informed supportive psychotherapy on the risk of self-harm acts and suicide attempts in patients with self-harm behavior and personality traits within the spectrum of borderline personality disorder. The trial will meet strict criteria for high quality randomized trials, and will hopefully help to establish evidence for the treatment of this patient group at higher risk of later suicide. There will be performed follow up interviews after 16 weeks, 28 weeks and 52 weeks.


Options:
A: Arm Label: CARMS therapy + TAU; Type: EXPERIMENTAL; Interventions: Other: Cognitive AppRoaches to coMbatting Suicidality (CARMS) | Arm Label: TAU; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Cognitive AppRoaches to coMbatting Suicidality (CARMS); Assigned to Arm(s): CARMS therapy + TAU
B: Arm Label: Cognitive Therapy; Type: OTHER; Interventions: Behavioral: Cognitive Therapy | Arm Label: Enriched Care; Type: OTHER; Interventions: Other: Enriched Care | Intervention Type: BEHAVIORAL; Name: Cognitive Therapy; Assigned to Arm(s): Cognitive Therapy | Intervention Type: OTHER; Name: Enriched Care; Assigned to Arm(s): Enriched Care
C: Arm Label: therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive behavioural therapy | Arm Label: Standard treatment; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard treatment | Intervention Type: BEHAVIORAL; Name: Cognitive behavioural therapy; Assigned to Arm(s): therapy | Intervention Type: OTHER; Name: Standard treatment; Assigned to Arm(s): Standard treatment
D: Arm Label: Dialectical Behavior Therapy DBT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DBT | Arm Label: CAMS; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: CAMS | Intervention Type: BEHAVIORAL; Name: DBT; Assigned to Arm(s): Dialectical Behavior Therapy DBT | Intervention Type: BEHAVIORAL; Name: CAMS; Assigned to Arm(s): CAMS

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Dialectical Behavior Therapy in Patient With Self Harming Behavior and Traits Within the Spectrum of Borderline Personality Disorder.
Brief Summary: Purpose: The purpose of this study is to investigate the efficacy of Dialectical Behavior Therapy (DBT) versus CAMS (Collaborative Assessment and Management of Suicidality) -informed supportive psychotherapy on the risk of self-harm acts and suicide attempts in patients with self behavior and personality traits within the spectrum of borderline personality disorder.

Hypothesis: The hypothesis is 16 weeks of treatment with Dialectical Behavior Therapy (DBT) after a defined manual has a higher efficacy than CAMS-informed supportive psychotherapy on self-harm acts, suicide attempts, suicidal ideation, depressive symptoms, impulsiveness and consumption of hospital services in patients with symptoms within the spectrum of borderline personality disorder (BDP).

Method: The investigators will include 160 patients in the randomized trial to investigate whether 16 weeks of DBT-treatment as a higher efficacy than CAMS-informed supportive psychotherapy on the risk of self-harm acts and suicide attempts in patients with self-harm behavior and personality traits within the spectrum of borderline personality disorder. The trial will meet strict criteria for high quality randomized trials, and will hopefully help to establish evidence for the treatment of this patient group at higher risk of later suicide. There will be performed follow up interviews after 16 weeks, 28 weeks and 52 weeks.


Options:
A: Arm Label: Prevention Program; Type: EXPERIMENTAL; Interventions: Behavioral: Prevention program | Arm Label: Assessment Only; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Prevention program; Assigned to Arm(s): Prevention Program
B: Arm Label: Positive Psychology; Type: EXPERIMENTAL; Interventions: Behavioral: Positive Psychology | Arm Label: Organizational Skills; Type: SHAM_COMPARATOR; Interventions: Behavioral: Control Condition | Intervention Type: BEHAVIORAL; Name: Positive Psychology; Assigned to Arm(s): Positive Psychology | Intervention Type: BEHAVIORAL; Name: Control Condition; Assigned to Arm(s): Organizational Skills
C: Arm Label: Dialectical Behavior Therapy DBT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DBT | Arm Label: CAMS; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: CAMS | Intervention Type: BEHAVIORAL; Name: DBT; Assigned to Arm(s): Dialectical Behavior Therapy DBT | Intervention Type: BEHAVIORAL; Name: CAMS; Assigned to Arm(s): CAMS
D: Arm Label: COPESS and Treatment as usual; Type: ACTIVE_COMPARATOR; Interventions: Other: COPESS | Arm Label: Treatment as usual only; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: COPESS; Assigned to Arm(s): COPESS and Treatment as usual

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Dialectical Behavior Therapy in Patient With Self Harming Behavior and Traits Within the Spectrum of Borderline Personality Disorder.
Brief Summary: Purpose: The purpose of this study is to investigate the efficacy of Dialectical Behavior Therapy (DBT) versus CAMS (Collaborative Assessment and Management of Suicidality) -informed supportive psychotherapy on the risk of self-harm acts and suicide attempts in patients with self behavior and personality traits within the spectrum of borderline personality disorder.

Hypothesis: The hypothesis is 16 weeks of treatment with Dialectical Behavior Therapy (DBT) after a defined manual has a higher efficacy than CAMS-informed supportive psychotherapy on self-harm acts, suicide attempts, suicidal ideation, depressive symptoms, impulsiveness and consumption of hospital services in patients with symptoms within the spectrum of borderline personality disorder (BDP).

Method: The investigators will include 160 patients in the randomized trial to investigate whether 16 weeks of DBT-treatment as a higher efficacy than CAMS-informed supportive psychotherapy on the risk of self-harm acts and suicide attempts in patients with self-harm behavior and personality traits within the spectrum of borderline personality disorder. The trial will meet strict criteria for high quality randomized trials, and will hopefully help to establish evidence for the treatment of this patient group at higher risk of later suicide. There will be performed follow up interviews after 16 weeks, 28 weeks and 52 weeks.


Options:
A: Arm Label: Dialectical Behavior Therapy DBT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DBT | Arm Label: CAMS; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: CAMS | Intervention Type: BEHAVIORAL; Name: DBT; Assigned to Arm(s): Dialectical Behavior Therapy DBT | Intervention Type: BEHAVIORAL; Name: CAMS; Assigned to Arm(s): CAMS
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioural Therapy, Other: Treatment as usual | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Treatment as usual | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioural Therapy; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Treatment as usual; Assigned to Arm(s): 1, 2
C: Arm Label: Short-term MBT; Type: EXPERIMENTAL; Interventions: Other: Short-term MBT | Arm Label: Long-term MBT; Type: ACTIVE_COMPARATOR; Interventions: Other: Long-term MBT | Intervention Type: OTHER; Name: Short-term MBT; Assigned to Arm(s): Short-term MBT | Intervention Type: OTHER; Name: Long-term MBT; Assigned to Arm(s): Long-term MBT
D: Arm Label: Brief Admission; Type: EXPERIMENTAL; Interventions: Other: Brief Admission | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Brief Admission; Assigned to Arm(s): Brief Admission

Answer: A